Other News

QT MEDICAL’S Online Order, Mail Delivery, XPRESS ECG Testing Service, to Exhibit at the World’s Largest Annual Trade Show

Enabling patients to conduct electrocardiogram (ECG) tests safely and efficiently at home using PCA 500, the only medical grade 12-lead Resting ECG approved by the FDA for patient use. LAS VEGAS, July 29, 2022 /PRNewswire/ — Demand for telehealth and home care has surged drastically during the pandemic. QT Medical Inc. (QT […]

LIMES Randomised Controlled Trial about Sirolimus Coated Balloon in BTK takes the first Stride: patient enrolment started

Concept Medical Inc., a pioneer in developing drug delivery device platforms for vascular intervention, has announced the initiation of LIMES trial. MÜNSTER, Germany, July 29, 2022 /PRNewswire/ — LIMES (Prospective Multi-Center Randomized Controlled Trial to Evaluate the Safety and Efficacy of SiroLIMus Drug Coated Balloon versus Standard Angioplasty for the Treatment of Infrapopliteal Occlusions […]

Appendix 4C Quarterly Activity Report

Mesoblast Operational and Financial Highlights for Quarter Ended June 30, 2022 NEW YORK, July 29, 2022 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the fourth quarter ended June 30, 2022. Financial highlights Net cash usage […]

LeMaitre Q2 2022 Financial Results

BURLINGTON, Mass., July 28, 2022 (GLOBE NEWSWIRE) — LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2022 results, announced a $0.125/share quarterly dividend and provided guidance. Q2 2022 Financial Results Sales of $42.1mm, +4% (+8% organic) vs. Q2 2021 Gross margin of 66.0% Op. income reported […]

CVRx Reports Second Quarter 2022 Financial and Operating Results

Second quarter 2022 revenue of $5.0 million, a 61% increase over prior year MINNEAPOLIS, July 28, 2022 (GLOBE NEWSWIRE) — CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for […]

Adagio Medical Announces Publication of Cryocure-2 Data Reporting 85% Freedom from AF at 12 Months After a Single Ablation Procedure in Patients with Persistent Atrial Fibrillation and Discusses Current Status of iCLAS™ Cryoablation System

LAGUNA HILLS, Calif., July 28, 2022 /PRNewswire/ — Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), announced the publication of the results of its Cryocure-2 ultra-low temperature cryoablation (ULTC) study in patients with AF in the Journal of American College of Cardiology […]

Caption Health and Heartbeat Health partner to provide unprecedented access to cardiac care

By combining AI-guided echocardiograms and Virtual-First cardiology care, the new partnership enables early disease identification and management for patients from the comfort of their homes BRISBANE, Calif. and NEW YORK, July 28, 2022 /PRNewswire/ — Caption Health, the leader in providing services and AI to improve heart ultrasound access, and Heartbeat Health, the nation’s largest Virtual […]

Integer Holdings Corporation Reports Second Quarter 2022 Results

~ 2Q22 sales and profit consistent with expectations ~ ~ Increasing 2022 sales and operating income outlook ~ PLANO, Texas, July 28, 2022 (GLOBE NEWSWIRE) — Integer Holdings Corporation (NYSE:ITGR), a leading medical device outsource manufacturer, today announced results for the three months ended July 1, 2022. Second Quarter 2022 Highlights (compared […]

Ionis announces positive topline results from Phase 2b clinical study of fesomersen, a potential novel anti-thrombotic treatment

Phase 2b RE-THINC ESRD study of fesomersen met its primary endpoint in patients with end-stage renal disease on hemodialysis Fesomersen demonstrated substantial and statistically significant reductions in Factor XI activity levels Fesomersen, a novel Factor XI antisense inhibitor designed to prevent thrombosis, was safe and well-tolerated in the study with up to […]